- Concept of "independent regulatory authorities" and its reflection in the Slovak legal framework2005 | Faculty of Mathematics and Physics
- On the conception of independent regulatory authorities with special regard to the problem of theirs independence2005 | Faculty of Mathematics and Physics
- Organisation of Public Administration2012 | Faculty of Law
- Economic approach to independent administrations2019 | Faculty of Law
- The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?2016 | First Faculty of Medicine
- Administrative Law from a comparative and European Perspective2017 | Faculty of Law
- Politics of Sexual Desire2022 | Publication without faculty affiliation
- Research update on aflatoxins toxicity, metabolism, distribution, and detection: A concise overview2023 | Publication without faculty affiliation
- Recent net neutrality judgements and their meaning for future of EU's technology regulation2022 | Faculty of Law
- European Protection of Retail Investors in Insurance-Based Investment Products: Product Interventions under PRIIPs2021 | Faculty of Law
- Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases2019 | First Faculty of Medicine
- Future MS care: a consensus statement of the MS in the 21st Century Steering Group2013 | First Faculty of Medicine
- Defining the critical hurdles in cancer immunotherapy2011 | Second Faculty of Medicine
- Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhihosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement2017 | Faculty of Medicine in Pilsen
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Routine combination of dual antiplatelet therapy with proton pump inhibitors - are we not throwing the baby out with the bath water?2013 | First Faculty of Medicine, Third Faculty of Medicine
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial2020 | First Faculty of Medicine